Dr. Lal PathLabs has announced the outcome of its Board Meeting held on November 04, 2026. Key decisions include the approval of un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company also declared a second interim dividend of INR 5/- per equity share for the financial year 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director, designated as a Non-Executive Independent Director.
Board Meeting Outcomes
Dr. Lal PathLabs Limited convened a Board Meeting on November 04, 2026, where several significant corporate actions were deliberated and approved. The meeting focused on financial performance, dividend distribution, and board composition.
Financial Results Approved
The Board of Directors approved the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. A signed copy of these results, along with the Limited Review Report from the Statutory Auditors, has been attached as ‘Annexure- A’.
Interim Dividend Declared
In a move beneficial to shareholders, the company declared a second interim dividend of INR 5/- per equity share. This represents a 50% payout on the face value of INR 10/- per share for the financial year 2026-27. The record date for the purpose of determining the eligible shareholders for this dividend is set as November 11, 2026. The dividend will be disbursed within 30 days of its declaration.
Board Appointment
Following the recommendation of the Nomination and Remuneration Committee, Ms. Vasuta Agarwal (DIN: 07480674) has been appointed as an Additional Director. She will serve as a Non-Executive Independent Director on the Board for a term of three consecutive years, commencing from November 04, 2026, subject to shareholder approval via postal ballot. Ms. Agarwal is confirmed not to be debarred from holding such an office.
Further Investment in Subsidiary
The Board also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (‘LPL Dubai’). This investment, to be made in one or more tranches, is intended to meet LPL Dubai’s business and operational requirements, including further investment in its subsidiary, Sunshine Healthcare Limited (‘SHL’), Ghana. The Board Meeting commenced at 11:49 AM IST and concluded at 01:20 PM IST.
Source: BSE
